我武生物：皮炎诊断贴剂02贴I期临床试验首例受试者入组，辅助诊断变应性接触性皮炎

Core Viewpoint - The company has initiated the first subject enrollment for the Phase I clinical trial of the "Dermatitis Diagnostic Patch 02" aimed at exploring its safety in patients with allergic contact dermatitis in China [1] Group 1: Product Development - The "Dermatitis Diagnostic Patch 02" is designed for patch testing to assist in diagnosing allergic contact dermatitis related to sensitizers such as carso, p-phenylenediamine, and formaldehyde [1] - This product expands the company's research pipeline in the field of allergic disease diagnostics, potentially addressing the allergen detection needs of a broader range of allergic disease patients [1] Group 2: Clinical Trial Progress - The product has officially entered Phase I clinical trials, although the results of these trials carry uncertainties [1] - Subsequent phases, including Phase II, Phase III clinical trials, and the application for market approval, will follow before the product can be commercially available, with progress and outcomes remaining uncertain [1]